Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mural Oncology PLC MURA

Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. As of December 4, 2025, Mural Oncology plc operates as a subsidiary of XOMA Royalty Corporation.


NDAQ:MURA - Post by User

Bullboard Posts
User Avatar Image
(187)
•••
  • coolfooldumbguyX
Post by coolfooldumbguyon Apr 15, 2025 1:35pm
26 Views
Post# 36539747

Using technical analysis for this one.

Using technical analysis for this one.Bought it early this morning and it's looking really good here for shareholders today
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities